Eric E. Lloyd

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

T. Huizinga, B. Souberbielle, E. Esfandiari, 2017, Arthritis Research & Therapy.